Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated ...

Dermavant Sciences Ltd. to Organon & Co. for $1.2 billion. The massive amount comprises an up-front $175 million payment, along with a potential $75 million regulatory milestone and up to $950 million ...

Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 ...

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...

The phase 3 TiNivo-2 study (NCT04987203), which evaluated the combination of nivolumab (Opdivo) and tivozanib (Fotivda) in ...

Who is Versant Vantage II, L.P.? Versant Vantage II, L.P. does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies ...

Tempest Therapeutics Inc (NASDAQ: TPST) has experienced a rise in its stock price by 5.04 compared to its previous closing price of 1.19. However, the company has seen a fall of -6.72% in its stock ...

Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated ...

Among those it is feared could face the chop is the multibillion-pound Tempest fighter jet programme which is set to build the UK's future flagship fighter jet in partnership with Japan and Italy.